Insider Transactions
Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
---|---|---|---|---|---|---|---|
Jul 18, 2018 | SVP/GM, Global Vascular | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,496 | -- | 9,496 | |
Aug 31, 2016 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 9,642 | $16.54 | 52,037 | |
Aug 31, 2016 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 9,642 | $16.54 | 61,151 | |
Jul 19, 2023 | SVP Global Operations and R&D | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,650 | -- | 37,939 | |
Aug 12, 2021 | SVP Global Operations and R&D | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,834 | -- | -- | |
Jul 15, 2016 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 9,844 | $16.20 | 37,081 | |
Jul 15, 2016 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 9,844 | $16.20 | 33,935 | |
Apr 08, 2024 | Director, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 10,000 | $6.70 | 539,066 | |
Oct 10, 2022 | Director, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 10,000 | $15.00 | 450,407 | |
Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | $10.63 | 30,754 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.